Table 3.
Incidence of adverse events associated with anticholinergic agents
| Adverse event | Darifenacin | Flavoxate∗ | Oxybutynin† | Solifenacin | Tolterodine | Trospium |
| Dry mouth | 20.2%–35.3% | ∗ | 29%–61% | 10.9%–27.6% | 23% | 20.1% |
| Constipation | 14.8%–21.3% | ∗ | 7%–13% | 5.4%–13.4% | 6% | 9.6% |
| Upper abdominal pain | 2.4%–3.9% | No report | <5 | 1.2%–1.9% | 4% | 1.5% |
| Dyspepsia | 2.7%–8.4% | ∗ | 5%–7% | 1.4%–3.9% | 3% | 1.2% |
| Nausea | 1.5%–2.7% | ∗ | 2%–9% | 1.7%–3.3% | ∗ | >0.5% |
| Diarrhea | 0.9%–2.1% | ∗ | 7%–9% | No report | ∗ | No report |
| Urinary retention | No report | ∗ | <5% | 1.4% | No report | 1.2% |
| Urinary tract infection | 4.5%–4.7% | No report | 5% | 2.8%–4.8% | 1% | 1.2% |
| Vertigo | 1.3%–2.1% | ∗ | 4%–6% | 1.9% | 2% | No report |
| Blurred vision | >1% | ∗ | 1%–8% | 3.8%–4.8% | 1% | >0.5% |
| Drowsiness | 0.9%–2.1% | ∗ | 2%–12% | 1.0%–2.1% | 3% | 1.9% |
| Headache | No report | ∗ | 6%–10% | No report | 6% | 4.2% |
| Dry eyes | 1.5%–2.1% | ∗ | 3%–6% | 0.3%–1.6% | 3% | No report |
∗Incidence not defined.
†Oxybutynin transdermal system adverse events also include local reactions (i.e., pruritus, erythema, vesicles, rash, or macules at the application site; see reference 14).